Loading...
Ten years of biosimilar recombinant human growth hormone in Europe
Recombinant human growth hormone (rhGH) has been in clinical use for more than 30 years. With the expiration of patent exclusivity for the first wave of rhGH products and other biopharmaceuticals, the opportunity emerged for the development of biosimilar medicines. A biosimilar is defined by the Eur...
Na minha lista:
| Udgivet i: | Drug Des Devel Ther |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5439961/ https://ncbi.nlm.nih.gov/pubmed/28553081 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S130317 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|